L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects

Neurology

Volumn 50, Issue 3, 1998, Pages 660-668

  Freedman, M ^a   Rewilak, D ^b   Xerri, T ^b   Cohen, S ^b   Gordon, A S ^b   Shandling, M ^b   Logan, A G ^b  

^a BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SELEGILINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PERSONALITY TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK BENEFIT ANALYSIS; TABLET; VERTIGO; XEROSTOMIA;

EID: 0031943163     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.3.660     Document Type: Article

References (62)

1. Knoll J. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine oxidase and its inhibition. Amsterdam: Elsevier, Excerpta Medica, North-Holland, 1976:135-161.
2. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology (Berl) 1978; 57:33-38.
3. Martini E, Pataky I, Szilagyi K, Venter V. Brief information on an early phase-II study with Deprenyl in demented patients. Pharmacopsychiatry 1987;20:256-257.
4. Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology (Berl) 1987;91:489-495.
5. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioural change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987;44:427-433.
6. Agnoli A, Martucci N, Fabbrini G, Fioravanti M. Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1990;1:109-114.
7. Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 1990;12:306-313.
8. Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC. Selegiline in the treatment of mild to moderate Alzheimer type dementia. Clin Ther 1990;12:315-322.
9. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13:147-163.
10. Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavior problems. J Clin Psychiatry 1991;52:342-345.
11. Falsaperla A, Preti PA, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer type dementia. Clin Ther 1990;12: 376-384.
12. Schneider LS, Pollock VE, Zemansky MF, Gleason RP, Palmer R, Sloane B. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatry Neurol 1991;4:143-148.
13. Mangoni A, Grassi M, Frattola L, et al. Effects of MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991;31:100-107.
14. Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type: influence of treatment with L-deprenyl. J Neural Transm Park Dis Dement Sect 1991;3:15-25.
15. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-1225.
16. Koivisto K, Helkala EL, Hanninen T, et al. Three-year follow-up of long-term selegiline treatment of Alzheimer's disease. J Neurol 1995;242(suppl 2):153. Abstract.
17. Riekkinen P, Koivisto K, Helkala E, et al. Long-term double-blind trial of selegiline in Alzheimer's disease. Neurobiol Aging 1996;15(suppl 1):S67. Abstract.
18. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both, as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
19. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 1980;27:1029-1034.
20. Alexopoulos GS, Lieberman KW, Young RC. Platelet MAO activity in primary degenerative dementia. Am J Psychiatry 1984;141:97-99.
21. Robinson DS, Davis JM, Nies A, Ravaris CL, Sylwester D. Relation of sex and aging to monoamine oxidase activity of human brain, plasma and platelets. Arch Gen Psychiatry 1971;24:536-539.
22. Reinikainen KJ, Paljarvi L, Halonen T, et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 1988;9:245-252.
23. Smith RC, Ho BT, Kralik P, Vroulis G, Gordon J, Wolff J. Platelet monoamine oxidase in Alzheimer's disease. J Gerontol 1982;37:572-574.
24. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-690.
25. Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993;8(suppl 1):S20-S30.
26. Folstein MF, Folstein S, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-1597.
28. McKhann G, Drachman DA, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
29. Rosen WG, Terry RD, Fuld PA, Katzman RD, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
30. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661-663.
31. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
32. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1361.
33. Alexopoulos GS, Abrams RC, Shamoian CA, Young RC. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271-284.
34. Raskin A, Crook T. Relative's Assessment of Global Symptomatology. Psychopharmacol Bull 1988;24:759.
35. Buschke H. Selective reminding for the analysis of memory and learning. J Verb Learn Verb Behav 1973;12:543-550.
36. Buschke H, Fuld PA. Evaluating storage, retention and retrieval in disordered memory and learning. Neurology 1974; 24:1019-1025.
37. Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK. Distinguishing normal and demented elderly with the Selective Reminding test. J Clin Exp Neuropsychol 1989;11: 615-630.
38. Hannay JH, Levin HS. Selective Reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985;7:251-263.
39. Benton AL, Hamsher K, Varney NR, Spreen O. Contributions to neuropsychological assessment. New York: Oxford University Press, 1983.
40. Mirsky A. Attention: a neuropsychological perspective. In: Jeanne S, ed. Education and the brain. Chicago: National Society for the Study of Education, 1978.
41. Strub RL, Black FW. The mental status examination in neurology. Philadelphia: F.A. Davis, 1977.
42. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
43. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch de Psychologie 1941;28:286-340.
44. Osterrieth PA. Le test de copie d'une figure complex: contribution a l'etude de la perception at de la memoire. Arch de Psychologie 1944;30:286-356.
45. Wechsler D. WAIS-R manual: Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation, 1981.
46. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984;39:187-193.
47. Guy W, Cleary P, Bonato RR. Methodological implications of a large central data system. Proceedings of IXth congress, CINP. Amsterdam: Excerpta Medica, 1975.
48. Tatton WG, Wadia JS, Redman R, Tatton NA. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal out-growth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm 1997(suppl 1);49:45-59.
49. Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm 1997(suppl 1);49:245-268.
50. Landfield P, Thibault O, Mazzanti M, Porter N, Kerr D. Mechanisms of neuronal death in brain aging and Alzheimer's disease: role of endocrine-mediated calcium dyshomeostasis. J Neurobiol 1992;23:1247-1260.
51. Loo D, Copani A, Pike C, Whittemore E, Walencewicz A, Cotman C. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Poc Natl Acad Sci USA 1993;90: 7951-7955.
52. Su J, Anderson A, Cummings B, Cotman C. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994;5:2529-2533.
53. Karoum F, Chuang L, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 1982;32:503-509.
54. Golbe LI, Langston JW, Shoulson I. Selegiline and Parkinson's disease: protective and symptomatic considerations. Drugs 1990;39:646-651.
55. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6:542-544.
56. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y. Metabolism of deprenyl, a selective monamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986;16:129-136.
57. Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 1994;38:64-74.
58. Tatton W, William YH, Ju WY, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in Parkinson's disease. Toronto: Academic Press, 1996: 209-220.
59. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(suppl 3):S171-S183.
60. Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994;26: 121-134.
61. Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 1990;40:1225-1230.
62. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.